RG6795
/ Regor, Roche
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 06, 2026
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
(clinicaltrials.gov)
- P1 | N=136 | Recruiting | Sponsor: Genentech, Inc. | Trial completion date: Jul 2029 ➔ Apr 2030 | Trial primary completion date: Jul 2029 ➔ Apr 2030
First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
January 13, 2026
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
(clinicaltrials.gov)
- P1 | N=136 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
October 16, 2025
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
(clinicaltrials.gov)
- P1 | N=136 | Not yet recruiting | Sponsor: Genentech, Inc.
Monotherapy • New P1 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1